Skip to main content
Premium Trial:

Request an Annual Quote

Syrrx Raises $20M for Structural Proteomics Efforts

NEW YORK, Oct 3 - Structural genomics company Syrrx said Tuesday it has completed a $20 million Series B round of venture financing.

MPM Asset Management led the private placement. Nicholas Galakatos, general partner at MPM Asset Management, will be joining Syrrx's board of directors.

Syrrx uses proprietary high throughput technology platforms to solve protein structures that can be used along with genomic and computational approaches to design novel pharmaceuticals.

The company’s tools were developed by engineers recruited from the automotive industry and enable an assembly line approach, significantly impacting the cost and speed of drug design, the company said.

" We've applied auto industry principles to the next step in genomic research," Peter Schultz, Syrrx’s director, said in a statement.

Syrrx currently has 18 employees and is located in San Diego.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.